Hit enter to search or ESC to close
Immuneering Corporation
  • ABOUT
    • Our Approach
    • Team
  • PLATFORM
  • PIPELINE
  • FOR INVESTORS
  • PUBLICATIONS
  • CONTACT
    • Inquiries
    • Locations
    • Join Our Team
  • ABOUT
    • Our Approach
    • Team
  • PLATFORM
  • PIPELINE
  • FOR INVESTORS
  • PUBLICATIONS
  • CONTACT
    • Inquiries
    • Locations
    • Join Our Team
Tag

Drug Pipelines Archives - Immuneering Corporation

immun-ops2020 In Publications

Humanized 3D tumor models that are mutually aligned with AACR GENIE patients predict IMM-1-104 activity in RAS-addicted tumors

Highlights of the initial IMM-1-104 Phase 1 PK, PD and safety data presented at AACR include (as of data cut-off date of April 10, 2023, including patients with pancreatic and…

Read More
immun-ops2020 In Publications

Pan-RAS IMM-1-104 activity in humanized 3D tumor models is independent of specific amino acid substitution

Title: Pan-RAS IMM-1-104 activity in humanized 3D tumor models is independent of specific amino acid substitution Virtual poster presented at AACR Special Conference Targeting RAS March 7, 2023 Presenter: Sarah…

Read More
immun-ops2020 In Publications

Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity

Broad response demonstrated through deep cyclic inhibition of MAPK pathway, independent of specific RAS mutation Phase 1/2a clinical trial with IMM-1-104 underway in patients with advanced solid tumors harboring RAS…

Read More
immun-ops2020 In Publications

Cyclic disruption of the mitogen-activated protein kinase (MAPK) pathway by the Dual MEK inhibitor, IMM-6-415, enhances PD-1 and CTLA-4 checkpoint blockade in RAS mutant tumors

KRAS is the most frequently altered RAS gene (~85%) and is often mutated in pancreatic ductal adenocarcinoma (PDAC; 95%), non-small cell lung cancer (NSCLC; 40%) and colorectal cancer (CRC; 45%)1….

Read More
immun-ops2020 In Publications

Head-to-head comparison of the dual-MEK inhibitor IMM-1-104 versus binimetinib in NRAS mutant melanoma models

Title: Head-to-head comparison of the dual-MEK inhibitor IMM-1-104 versus binimetinib in NRAS mutant melanoma models Date: January 6, 2022 Presenter: Peter King, Ph.D., Immuneering Vice President, Head of Discovery Virtual…

Read More
Immuneering logo
  • ABOUT
  • PLATFORM
  • PIPELINE
  • PUBLICATIONS
  • FOR INVESTORS
  • CONTACT
  • Terms of Use
  • Privacy Policy

© 2023 Immuneering Corporation.